Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 15/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702835 | 0.88 | DPP4 (0.39) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2702832 | 0.83 | DPP4 (0.44) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL4404836 | 0.81 | DPP4 (0.54) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL2702812 | 0.81 | DPP4 (0.53) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2705049 | 0.79 | DPP4 (0.39) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2703644 | 0.78 | DPP4 (0.39) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2701680 | 0.77 | HPGD (0.40) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2706200 | 0.75 | TP53 (0.40) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL4404901 | 0.74 | DPP4 (0.43) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL4020045 | 0.74 | DPP4 (0.45) | DPP4DPP8DPP9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 7/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.